Behandling af hepatitis C hos børn med direktevirkende antiviral medicin

Krestine Rosager Hansen; Jesper Kjaergaard; Helene Kvistgaard; Dorthe Grosen; Mette Holm; Jan Gerstoft; Sannie Nordly; Thora Wesenberg Helt; Vibeke Brix Christensen

doi:10.61409/V08230522

Behandling af hepatitis C hos børn med direktevirkende antiviral medicin

Krestine Rosager Hansen, Jesper Kjaergaard, Helene Kvistgaard, Dorthe Grosen, Mette Holm, Jan Gerstoft, Sannie Nordly, Thora Wesenberg Helt, Vibeke Brix Christensen^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

9 Downloads (Pure)

Abstract

The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

Bidragets oversatte titel	Treatment of hepatitis C in children with direct-acting antiviral drugs
Originalsprog	Dansk
Artikelnummer	V08230522
Tidsskrift	Ugeskrift for Læger
Vol/bind	186
Udgave nummer	10
ISSN	0041-5782
DOI	https://doi.org/10.61409/V08230522
Status	Udgivet - 13. maj 2024

Emneord

Antiviral Agents/adverse effects
Child
Hepacivirus
Hepatitis C
Hepatitis C, Chronic/drug therapy
Humans
Liver Cirrhosis/complications

Dokumenter og links

10.61409/V08230522Licens: CC BY-NC-ND

Open Access VersionForlagets udgivne version, 244 KBLicens: CC BY-NC-ND

Citationsformater

@article{331a549eb1434657ba47e7c30b58967b,

title = "Behandling af hepatitis C hos b{\o}rn med direktevirkende antiviral medicin",

abstract = "The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.",

keywords = "Antiviral Agents/adverse effects, Child, Hepacivirus, Hepatitis C, Hepatitis C, Chronic/drug therapy, Humans, Liver Cirrhosis/complications",

author = "{Rosager Hansen}, Krestine and Jesper Kjaergaard and Helene Kvistgaard and Dorthe Grosen and Mette Holm and Jan Gerstoft and Sannie Nordly and Helt, {Thora Wesenberg} and Vibeke Brix Christensen",

year = "2024",

month = may,

day = "13",

doi = "10.61409/V08230522",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "10",

}

TY - JOUR

T1 - Behandling af hepatitis C hos børn med direktevirkende antiviral medicin

AU - Rosager Hansen, Krestine

AU - Kjaergaard, Jesper

AU - Kvistgaard, Helene

AU - Grosen, Dorthe

AU - Holm, Mette

AU - Gerstoft, Jan

AU - Nordly, Sannie

AU - Helt, Thora Wesenberg

AU - Brix Christensen, Vibeke

PY - 2024/5/13

Y1 - 2024/5/13

N2 - The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

AB - The primary purpose of treating chronic hepatitis C (HCV) is to prevent the development of liver fibrosis, cirrhosis, and cancer. In the last decade, direct-acting antiviral medicine (DAA) has been approved to treat children with HCV. This treatment has a higher efficacy, shorter duration, and milder side effects than the previously approved treatment. In this review, it is recommended to track down children who might be infected with HCV to enhance early treatment to prevent transmission of the virus and the possible complications.

KW - Antiviral Agents/adverse effects

KW - Child

KW - Hepacivirus

KW - Hepatitis C

KW - Hepatitis C, Chronic/drug therapy

KW - Humans

KW - Liver Cirrhosis/complications

U2 - 10.61409/V08230522

DO - 10.61409/V08230522

M3 - Tidsskriftartikel

C2 - 38235776

SN - 0041-5782

VL - 186

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 10

M1 - V08230522

ER -

Behandling af hepatitis C hos børn med direktevirkende antiviral medicin

Abstract

Emneord

Dokumenter og links

Fingeraftryk

Citationsformater